Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ADCYAP1R1 | P41586 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225192 | 1.00 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL1225193 | 1.00 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL2782478 | 1.00 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL1225195 | 1.00 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL12881201 | 0.86 | TRPM5 (0.81) | TRPM5ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL3862190 | 0.86 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL1223594 | 0.86 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL1223595 | 0.86 | TRPM5 (1.00) | TRPM5ALDH1A1POLBHTTLMNA | |
| SCHEMBL3974398 | 0.80 | TRPM5 (0.80) | TRPM5ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL14417616 | 0.80 | TRPM5 (0.80) | TRPM5ALDH1A1LMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | REDPOINT BIO CORPORATION | 2011-02-10 | — | — | US | disclosed |
| WO-2010132615-A1 | HYDRAZONE COMPOUNDS AND THEIR USE | STEIN PHILIP (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033393-A1 | Hydrazone Compounds and Their Use | TRPM5, TRPV5, TRPM8 | TRPM5 1/4885ALDH1A1 493/4885POLB 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.